MedTrace Logo

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

NCT07048353 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-07-02

No results posted yet for this study

Summary

The is a prospective, open-label, dose-climbing multicenter clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。

Conditions

  • Lymphoma
  • B Cell Lymphoma
  • CD30+ Peripheral T-cell Lymphoma

Interventions

DRUG

chimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CD30 CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Sponsors & Collaborators

  • Tongji Hospital Affiliated to Tongji Medical College of HUST

    collaborator UNKNOWN

  • Shanxi Bethune Hospital

    collaborator OTHER

  • Wuhan Central Hospital

    collaborator OTHER

  • Yichang Central People's Hospital

    collaborator OTHER

  • First Affiliated Hospital of Guangxi Medical University

    collaborator OTHER

  • Shandong Qilu Cell Therapy Engineering Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-28
Primary Completion
2029-07-28
Completion
2029-07-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07048353 on ClinicalTrials.gov